Lung Cancer Screening: Who Low-Dose CT Is Actually For

Low-dose CT lung screening is not a test everyone should ask for. It is offered to a narrow group defined by age and smoking history, repeated annually, and it earns its place in that group and largely nowhere else. That narrowness is the whole design. Lung cancer is one of the leading causes of cancer death worldwide, and it is notorious for staying silent until it is advanced ¹, so a test that finds it early sounds like something everybody should have. The reason nobody recommends that is arithmetic, and it is worth understanding before you either request a scan or decline one.

What the scan is

A low-dose CT is a chest scan that takes a few seconds, needs no injection, and does not require you to change out of most clothing. You lie on the table, hold your breath once, and it is done. The “low-dose” part means it uses a fraction of the radiation of a standard diagnostic chest CT, which matters when the plan is to repeat it every year for a decade or more.

What it produces is a detailed picture of the lungs in cross-section, detailed enough to see nodules a few millimetres across. That sensitivity is the source of both its value and its main side effect, which I will come back to.

It is a screening test, which means it is done in people with no symptoms. If you have a persistent cough, coughing blood, unexplained weight loss, or breathlessness that is new, that is a reason to see a clinician now, not a reason to book a screen. Symptoms take you into diagnostic territory, and the pathway is different and faster.

Who it is for

Eligibility rests on two things: age and smoking history. A widely used rule offers annual low-dose CT to adults roughly 50 to 80 years old who have about a 20 pack-year smoking history and who either still smoke or stopped within the past 15 years ². Some countries use a lower age band, some use a higher pack-year threshold, and several national programmes now use a risk-prediction calculator that folds in age, smoking, family history, and other factors rather than a single cut-off. The principle is constant even where the numbers move: screening is aimed at people whose baseline risk is high enough that finding something is likely to be real.

A pack-year is one pack a day for one year, so 20 a day for 20 years and 40 a day for 10 years both come to 20 pack-years. People routinely underestimate theirs. If you are close to a threshold, it is worth doing the sum properly rather than deciding from memory.

The 15-year rule about quitting catches people out. Risk falls after stopping, but it does not fall to never-smoked levels for a long time, which is why former smokers remain eligible for years. If you quit two decades ago you generally fall outside standard eligibility, which is a good outcome rather than a snub.

Why never-smokers are not screened

This is the question I get asked most, usually by someone whose lungs feel like a black box. Lung cancer does occur in people who never smoked, and it is a real and under-discussed group. But the population-level maths does not support screening them. Tobacco remains by far the dominant cause of lung cancer worldwide ³, so in never-smokers the chance that a given scan finds a cancer is low, while the chance it finds a small benign nodule stays high. Screen a low-risk population and you generate mostly follow-up, not mostly diagnoses. This is the same mechanism that runs underneath the harms of over-testing and overdiagnosis.

Specific exposures are a separate conversation. Occupational asbestos, radon, or certain industrial dusts, and in some cases a strong family history, can shift an individual’s risk enough to be worth raising directly with a clinician. That is a personalised discussion, not a general recommendation.

The annual schedule, and why it matters

Lung screening is not a one-off. The evidence supporting it comes from programmes that scanned people repeatedly, and the value lies in the interval as much as in the image ⁴. A single clear scan tells you about today. It cannot tell you about the nodule that appears in year four.

This has a practical consequence people underweight when they book: signing up is a commitment to a schedule, and dropping out after one reassuring scan gets you most of the downside and little of the benefit. If the yearly return does not sound sustainable, that is worth saying out loud before starting rather than three years in.

Nodules, and the follow-up you should expect

Here is the part the leaflet buries. Low-dose CT finds nodules in a large share of the people it scans, and the overwhelming majority are benign, frequently scar tissue from an infection you had and forgot about. A finding is the expected output of the test, not evidence something has gone wrong.

Radiologists handle this with structured reporting: nodules are graded by size and appearance, and each grade has a defined next step. For most small findings, that step is another scan at three, six, or twelve months to see whether it has changed, because growth over time is far more informative than size at one moment. Only a minority progress to a PET scan or a biopsy.

Knowing this in advance does not eliminate the wait, but it reframes it. A letter mentioning a nodule is usually the system working as designed, not the beginning of bad news. It is also the clearest illustration of a distinction worth holding onto, which is that a screening test and a diagnostic test are not the same thing: the first says “look again”, only the second says what something is.

The trade-offs, stated plainly

The benefit is real. Randomised trials of annual low-dose CT in high-risk smokers found fewer lung cancer deaths in the screened groups, which is what moved multiple guideline bodies to recommend it for that population ². That is a meaningful result for a cancer that usually announces itself late.

The costs are also real. There are false positives and the follow-up they trigger. There is overdiagnosis, meaning some cancers found would never have caused harm in that person’s lifetime, and there is no way to know at the time which ones those are. There is cumulative radiation across years of scanning, small per scan but not nothing. And there is the risk that a clear scan is read as permission to keep smoking, which is the one outcome that turns a beneficial programme into a harmful one for the individual.

Which is why every serious programme pairs the scan with stop-smoking support. Quitting lowers lung cancer risk more than any screening test can, and no scan substitutes for it ³.

Working out whether it applies to you

Three questions get most people to an answer. What is my age? What is my honest pack-year total? Did I stop smoking, and if so when? If those three land you inside your country’s eligibility band, screening is worth a conversation with a clinician, who can talk through what a positive result would mean for you and whether you are willing to follow the schedule. If they land you well outside it, the highest-value action is not a scan.

I found this one clarifying to research, because it is the clearest example on the site of a good test aimed carefully. The same scan that saves lives in one group mostly manufactures worry in another, and nothing about the machine changes between the two. That is what building your own screening plan keeps running into: the question is never just whether a test works, but whether it works for you.

This article is general information, not medical advice. Whether lung screening is appropriate for you depends on your age, smoking history, exposures, and other conditions; discuss it with a qualified clinician.